252 results on '"Riemekasten, G"'
Search Results
2. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
3. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE
4. OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE
5. AB0919 DYNAMIC OPTICAL COHERENCE TOMOGRAPHY MIGHT BE A VALUABLE TOOL TO ASSESS THERAPEUTIC EFFICACY OF VASOACTIVE THERAPY IN SYSTEMIC SCLEROSIS
6. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
7. POS0150 AUTOANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR (FGF-2), PLACENTAL GROWTH FACTOR (PLGF) AND BETA-ADRENERGIC RECEPTOR 1 (ADRB1) IN AN ALTERED NETWORK OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS
8. POS0875 AUTOANTIBODIES DIRECTED TO G-PROTEIN COUPLED RECEPTORS CORRELATE WITH DISEASE ACTIVITY SCORES IN PATIENTS WITH PSORIATIC ARTHRITIS
9. POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT
10. AB0157 SYNERGISTIC EFFECT OF AT1R-AUTOANTIBODIES AND EXTRACELLULAR VESICLES IN SSC PATHOGENESIS
11. POS1161 RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY
12. S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
13. Therapy satisfaction and health literacy are key factors to improve medication adherence in systemic sclerosis
14. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR
15. Progressive interstitial lung disease is frequent also in late disease stages in systemic sclerosis patients from EUSTAR
16. Risk stratification approaches perform differently in SSc-associated PAH in EUSTAR
17. POS0140 PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT
18. POS0914 LATE SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR COHORT
19. AB0028 IL-2 DEPRIVED PHENOTYPE OF FOXP3+ REGULATORY T CELLS AND PHENOTYPIC ALTERATIONS CONVENTIONAL CD4+ T CELLS IN PATIENTS WITH INFLAMMATORY MYOPATHIES AND PRIMARY SJOGREN´S SYNDROME
20. AB0137 SERA DERIVED EXTRACELLULAR VESICLES FROM SYTEMIC SCLEROSIS PATIENT AND AUTOANTIBODIES MEDIATE PERIPHAL BLOOD MONOCYTES ACTIVATION
21. POS0829 SPECTRUM OF ANCA-SPECIFICITIES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS IN A RETROSPECTIVE MULTICENTER STUDY
22. POS0387 RISK STRATIFICATION APPROACHES PERFORM DIFFERENTLY IN SSc-ASSOCIATED PAH IN EUSTAR
23. AB0660 Long-term effect of combination therapy with rituximab and mycophenolic acid on cardiac manifestations, pulmonary function and skin fibrosis in systemic sclerosis
24. POS1287 INFLUENCES ON FIBROMYALGIA AND AUTOANTIBODIES DIRECTED TO NEURO- AND VASOREGULATORY MOLECULES NEED TO BE CONSIDERED IN BIOMARKER RESEARCH
25. POS0854 BASELINE CHARACTERISTICS OF PATIENTS WITH IMPROVEMENT OR PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) DURING THE SENSCIS TRIAL
26. POS0063 PROGRESSIVE INTERSTITIAL LUNG DISEASE IS FREQUENT ALSO IN LATE DISEASE STAGES IN SYSTEMIC SCLEROSIS PATIENTS FROM EUSTAR
27. POS1203 INCREASED PROTEASE-ACTIVATED RECEPTOR 1 AUTOANTIBODIES ARE ASSOCIATED WITH SEVERE COVID-19
28. POS0872 SERUM LEVEL OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS LINKED TO BETA2-MICROGLOBULINE, NT-PRO BNP AND HIGH-SENSITIVITY TROPONIN T AND MAY HELP TO IDENTIFY PATIENTS WITH EARLY CLINICAL PROGRESS IN SSc.
29. POS0471 INDUCED ANTIBODIES DIRECTED TO THE ANGIOTENSIN RECEPTOR TYPE 1 PROVOKE SKIN AND LUNG INFLAMMATION AND DERMAL FIBROSIS AND ACT SPECIES OVERARCHING
30. POS0474 ACTIVATION AND HYPERSENSITIZATION OF THE ANGIOTENSIN II TYPE 1 AND ENDOTHELIN-1 TYPE A RECEPTORS BY AGONISTIC AUTOANTIBODIES CONTRIBUTES TO VASCULAR INJURY IN SCLERODERMA RENAL CRISIS
31. OP0158 COHORT ENRICHMENT STRATEGIES FOR PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS FROM EUSTAR
32. Der außergewöhnliche Nachahmer einer Polymyositis
33. Efficacité du nintédanib chez des patients présentant une pneumopathie interstitielle diffuse associée à la sclérodermie systémique (PID-ScS) avec atteinte des organes internes : données de l’étude SENSCIS
34. OP0266 EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL
35. POS1449 SEGMENTED SHORT-FORMAT ONLINE EDUCATION SIGNIFICANTLY INCREASES PREDICTION, PROGNOSIS, AND MANAGEMENT OF FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
36. OP0054 NEW ROLE FOR PROTEINASE 3 IN IL-16 BIOACTIVITY CONTROL IN GRANULOMATOSIS WITH POLYANGIITIS
37. POS0834 LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS
38. POS0335 THE POTENTIAL ROLE OF IL13 IN VASCULOPATHY IN SYSTEMIC SCLEROSIS PATIENTS
39. OP0244 28 NEW AUTOANTIBODIES AGAINST GPCR, GROWTH FACTORS AND GROWTH FACTOR RECEPTORS ARE ASSOCIATED WITH DISEASE MANIFESTATIONS IN SYSTEMIC SCLEROSIS
40. POS0318 CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I POSITIVITY AND LIMITED CUTANEOUS FORM: DATA FROM THE EUSTAR DATABASE
41. Efficacité et tolérance du nintédanib chez des patients atteints de pneumopathie interstitielle diffuse associée à la sclérodermie systémique (SSc-PID) en fonction de l’indice de masse corporelle (IMC) à l’inclusion : analyse en sous-groupes de l’étude SENSCIS
42. Le taux de déclin de la fonction pulmonaire est-il le même chez les patients atteints d’une pneumopathie interstitielle diffuse associée à la sclérodermie systémique (PID-ScS) qui présentent une perte de poids ? Données de l’étude SENSCIS
43. Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis
44. The first composite score predicting Digital Ulcers in systemic sclerosis patients using Clinical data, Imaging and Patient history—CIP-DUS
45. THU0363 EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND NORMAL VERSUS ELEVATED C-REACTIVE PROTEIN (CRP) AT BASELINE: ANALYSES FROM THE SENSCIS TRIAL
46. THU0025 MICRO-RNA DIFFERENTIALLY REGULATE THE ALTERNATIVE PRTN3-MRNA IN GRANULOMATOSIS WITH POLYANGIITIS
47. AB0159 INTERLEUKIN-16 PLAYS A ROLE IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS
48. AB0166 IMMUNOGLOBULIN G DERIVED FROM PATIENTS WITH SYSTEMIC SCLEROSIS IMPRINTS A PRO-INFLAMMATORY AND PRO-FIBROTIC PHENOTYPE IN MONOCYTE-LIKE THP-1 CELLS
49. FRI0001 NEUTROPHILS IN GRANULOMATOSIS WITH POLYANGIITIS DISPLAY FEATURES OF PYROPTOSIS
50. AB0496 AUTOANTIBODIES TARGETING COMPLEMENT RECEPTORS 3A AND 5A1 ARE DECREASED IN ANCA-ASSOCIATED VASCULITIS AND CORRELATE WITH HIGHER RELAPSE RATE.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.